Rosetta Genomics this week announced that it has generated preliminary data showing that blood-based microRNAs can be used to identify and stratify heart failure patients.
The company did not, however, provide specific details regarding the miRNAs themselves.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
